HRP20161194T1 - Anti-bcma protutijela - Google Patents
Anti-bcma protutijela Download PDFInfo
- Publication number
- HRP20161194T1 HRP20161194T1 HRP20161194TT HRP20161194T HRP20161194T1 HR P20161194 T1 HRP20161194 T1 HR P20161194T1 HR P20161194T T HRP20161194T T HR P20161194TT HR P20161194 T HRP20161194 T HR P20161194T HR P20161194 T1 HRP20161194 T1 HR P20161194T1
- Authority
- HR
- Croatia
- Prior art keywords
- seq
- variable domain
- chain variable
- antibody
- antigen
- Prior art date
Links
- 239000000427 antigen Substances 0.000 claims 19
- 102000036639 antigens Human genes 0.000 claims 19
- 108091007433 antigens Proteins 0.000 claims 19
- 239000012634 fragment Substances 0.000 claims 19
- 150000001413 amino acids Chemical class 0.000 claims 18
- 210000003719 b-lymphocyte Anatomy 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 208000035475 disorder Diseases 0.000 claims 4
- 206010025323 Lymphomas Diseases 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 230000036210 malignancy Effects 0.000 claims 3
- 229920001184 polypeptide Polymers 0.000 claims 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- 206010002412 Angiocentric lymphomas Diseases 0.000 claims 2
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 208000011691 Burkitt lymphomas Diseases 0.000 claims 2
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims 2
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims 2
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims 2
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims 2
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims 2
- 206010028417 myasthenia gravis Diseases 0.000 claims 2
- 210000004180 plasmocyte Anatomy 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 206010001935 American trypanosomiasis Diseases 0.000 claims 1
- 208000002267 Anti-neutrophil cytoplasmic antibody-associated vasculitis Diseases 0.000 claims 1
- 208000036170 B-Cell Marginal Zone Lymphoma Diseases 0.000 claims 1
- 208000024699 Chagas disease Diseases 0.000 claims 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims 1
- 208000003807 Graves Disease Diseases 0.000 claims 1
- 208000015023 Graves' disease Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 206010053574 Immunoblastic lymphoma Diseases 0.000 claims 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 1
- 208000011200 Kawasaki disease Diseases 0.000 claims 1
- 201000003791 MALT lymphoma Diseases 0.000 claims 1
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims 1
- 208000010190 Monoclonal Gammopathy of Undetermined Significance Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 206010029461 Nodal marginal zone B-cell lymphomas Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 241000721454 Pemphigus Species 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 206010002022 amyloidosis Diseases 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 201000003444 follicular lymphoma Diseases 0.000 claims 1
- 208000025750 heavy chain disease Diseases 0.000 claims 1
- 210000004408 hybridoma Anatomy 0.000 claims 1
- 230000004957 immunoregulator effect Effects 0.000 claims 1
- 210000004698 lymphocyte Anatomy 0.000 claims 1
- 208000006116 lymphomatoid granulomatosis Diseases 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 201000007924 marginal zone B-cell lymphoma Diseases 0.000 claims 1
- 208000021937 marginal zone lymphoma Diseases 0.000 claims 1
- 201000005328 monoclonal gammopathy of uncertain significance Diseases 0.000 claims 1
- 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 201000006292 polyarteritis nodosa Diseases 0.000 claims 1
- 208000017805 post-transplant lymphoproliferative disease Diseases 0.000 claims 1
- 201000006037 primary mediastinal B-cell lymphoma Diseases 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 230000002685 pulmonary effect Effects 0.000 claims 1
- 201000008158 rapidly progressive glomerulonephritis Diseases 0.000 claims 1
- 201000006845 reticulosarcoma Diseases 0.000 claims 1
- 208000029922 reticulum cell sarcoma Diseases 0.000 claims 1
- 229960004641 rituximab Drugs 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Claims (16)
1. Izolirano protutijelo ili njegov antigen-vezujući fragment koji se veže za polipeptid SEQ ID NO:9, pri čemu protutijelo ili njegov antigen-vezujući fragment sadrže:
a) varijabilnu domenu teškog lanca koja sadrži CDR1 regiju koja sadrži aminokiseline 31-35 iz SEQ ID NO:3, CDR2 regiju koja sadrži aminokiseline 50-66 iz SEQ ID NO:3 i CDR3 regiju koja sadrži aminokiseline 99-106 iz SEQ ID NO:3; i varijabilnu domenu lakog lanca koja sadrži CDR1 regiju koja sadrži aminokiseline 24-38 iz bilo kojeg od SEQ ID NO: 4, 11 ili 12, CDR2 regiju koja sadrži aminokiseline 54-60 iz bilo kojeg od SEQ ID NO: 4, 11 ili 12 i CDR3 regiju koja sadrži aminokiseline 93-101 iz bilo kojeg odSEQ ID NO: 4, 11 ili 12;
b) varijabilnu domenu teškog lanca koja sadrži CDR1 regiju koja sadrži aminokiseline 31-35 iz SEQ ID NO:5, CDR2 regiju koja sadrži aminokiseline 50-66 iz SEQ ID NO:5 i CDR3 regiju koja sadrži aminokiseline 99-106 iz SEQ ID NO:5; i varijabilnu domenu lakog lanca koja sadrži CDR1 regiju koja sadrži aminokiseline 24-38 iz SEQ ID NO: 6, CDR2 regiju koja sadrži aminokiseline 54-60 iz SEQ ID NO: 6 i CDR3 regiju koja sadrži aminokiseline 93-101 iz SEQ ID NO: 6; ili
c) varijabilnu domenu teškog lanca koja sadrži CDR1 regiju koja sadrži aminokiseline 31-35 iz SEQ ID NO:7, CDR2 regiju koja sadrži aminokiseline 50-66 iz SEQ ID NO:7 i CDR3 regiju koja sadrži aminokiseline 99-106 iz SEQ ID NO:7; i varijabilnu domenu lakog lanca koja sadrži CDR1 regiju koja sadrži aminokiseline 24-38 iz SEQ ID NO: 8, CDR2 regiju koja sadrži aminokiseline 54-60 iz SEQ ID NO: 8 i CDR3 regiju koja sadrži aminokiseline 93-101 iz SEQ ID NO: 8.
2. Protutijelo ili antigen-vezujući fragment iz patentnog zahtjeva 1, pri čemu protutijelo ili antigen-vezujući fragment sadrži:
a) varijabilnu domenu teškog lanca koja sadrži SEQ ID NO: 3 i varijabilnu domenu lakog lanca koja sadrži SEQ ID NO: 12;
b) varijabilnu domenu teškog lanca koja sadrži SEQ ID NO: 3 i varijabilnu domenu lakog lanca koja sadrži SEQ ID NO: 4;
c) varijabilnu domenu teškog lanca koja sadrži SEQ ID NO: 3 i varijabilnu domenu lakog lanca koja sadrži SEQ ID NO: 11;
d) varijabilnu domenu teškog lanca koja sadrži SEQ ID NO: 5 i varijabilnu domenu lakog lanca koja sadrži SEQ ID NO: 6; ili
e) varijabilnu domenu teškog lanca koja sadrži SEQ ID NO: 7 i varijabilnu domenu lakog lanca koja sadrži SEQ ID NO: 8.
3. Protutijelo ili antigen-vezujući fragment iz patentnog zahtjeva 1, pri čemu protutijelo ili antigen-vezujući fragment sadrži:
a) teški lanac koji sadrži SEQ ID NO: 15 i laki lanac koji sadrži SEQ ID NO: 16 ili SEQ ID NO: 17;
b) teški lanac koji sadrži SEQ ID NO: 18 i laki lanac koji sadrži SEQ ID NO: 19; ili
c) teški lanac koji sadrži SEQ ID NO: 20 i laki lanac koji sadrži SEQ ID NO: 21.
4. Protutijelo ili antigen-vezujući fragment iz patentnog zahtjeva 1, pri čemu protutijelo ili antigen-vezujući fragment sadrži:
a) varijabilnu domenu teškog lanca koja sadrži slijed koji je najmanje 95% identičan slijedu odabranom između SEQ ID NO: 25-29 i varijabilnu domenu lakog lanca koja sadrži slijed koji je najmanje 95% identičan slijedu odabranom između SEQ ID NO: 22-24;
b) varijabilnu domenu teškog lanca koja sadrži slijed koji je najmanje 95% identičan slijedu odabranom između SEQ ID NO: 34-38 i varijabilnu domenu lakog lanca koja sadrži slijed koji je najmanje 95% identičan slijedu odabranom između SEQ ID NO: 30-33; ili
c) varijabilnu domenu teškog lanca koja sadrži slijed koji je najmanje 95% identičan slijedu odabranom između SEQ ID NO: 43-47 i varijabilnu domenu lakog lanca koja sadrži slijed koji je najmanje 95% identičan slijedu odabranom između SEQ ID NO: 39-42.
5. Protutijelo ili antigen-vezujući fragment iz patentnog zahtjeva 4, pri čemu protutijelo ili antigen-vezujući fragment sadrži:
a) varijabilnu domenu teškog lanca koja sadrži bilo koju od SEQ ID NO: 25-29 i varijabilnu domenu lakog lanca koja sadrži bilo koju od SEQ ID NO: 22-24;
b) varijabilnu domenu teškog lanca koja sadrži SEQ ID NO: 34-38 i varijabilnu domenu lakog lanca koja sadrži SEQ ID NO: 30-33; ili
c) varijabilnu domenu teškog lanca koja sadrži SEQ ID NO: 43-47 i varijabilnu domenu lakog lanca koja sadrži SEQ ID NO: 39-42.
6. Protutijelo iz bilo kojeg od patentnih zahtjeva 1-2, pri čemu je protutijelo kimerno ili jednolančano protutijelo.
7. Protutijelo iz patentnog zahtjeva 1, pri čemu je protutijelo humanizirano protutijelo.
8. Polipeptid koji se veže za SEQ ID NO:9 i sadrži antigen-vezni dio, Fab fragment, ili F(ab')2 fragment protutijela iz bilo kojeg od patentnih zahtjeva 1-7.
9. Hibridoma koja stvara protutijelo iz bilo kojeg od patentnih zahtjeva 1-7.
10. Farmaceutski sastav koji sadrži:
a) protutijelo ili antigen-vezujući fragment iz bilo kojeg od patentnih zahtjeva 1-7; ili
b) polipeptid iz patentnog zahtjeva 8.
11. Protutijelo ili antigen-vezujući fragment iz bilo kojeg od patentnih zahtjeva 1-7 za uporabu u liječenju poremećaja povezanog s B-stanicama.
12. Protutijelo ili antigen-vezujući fragment za uporabu kao u patentnom zahtjevu 11, gdje je poremećaj povezan s B-stanicama plazmocitom, Hodgkinov limfom, folikularni limfom, limfom mailh nezarezanih stanica, endemski Burkittov limfom, sporadični Burkitov limfom, limfom marginalne zone, ekstranodalni limfom limfoidnog tkiva povezanog s mukozom, nodalni monocitoidni B-stanični limfom, limfom slezene, limfom plaštenih stanica, limfom velikih stanica, difuzni limfom miješanih stanica, imunoblastični limfom, primarni medijastinalni B-stanični limfom, plućni B-stanični angiocentrični limfom, limfom malih limfocita, B-stanične proliferacije nepoznatog malignog potencijala, limfomatoidna granulomatoza, post-transplantacijski limfoproliferativni poremećaj, imunoregulatorni poremećaj, reumatoidni artritis, mijastenija gravis, idiopatska trombocitopenična purpura, antifosfolipidni sindrom, Chagasova bolest, Graveova bolest, Wegenerova granulomatoza, poliarteritis nodoza, Sjogrenov sindrom, obični pemfigus, skleroderma, multipla skleroza, antifosfolipidni sindrom, vaskulitis povezan s ANCA-om, Goodpasteureova bolest, Kawasakijeva bolest, autoimuna hemolitička anemija, brzoprogredirajući glomerulonefritis, bolest teških lanaca, primarna ili s imunocitima povezana amiloidoza, ili monoklonska gamopatija neodređenog značenja.
13. Protutijelo ili antigen-vezujući fragment za uporabu kao u patentnom zahtjevu 12, gdje je poremećaj povezan s B-stanicama
a) malignitet B-stanica, kao što je malignitet plazma stanica;
b) autoimuna bolest;
c) idiopatska trombocitopenična purpura;
d) mijastenija gravis; ili
e) autoimuna hemolitička anemija.
14. Protutijelo ili antigen-vezujući fragment za uporabu kao u patentnom zahtjevu 13, gdje je malignitet plazma stanica multipli mijelom.
15. Protutijelo ili antigen-vezujući fragment za uporabu kao u patentnom zahtjevu 13, gdje je autoimuna bolest sustavni eritematozni lupus ili reumatoidni artritis.
16. Protutijelo ili antigen-vezujući fragment za uporabu kao u patentnom zahtjevu 11 ili 12, gdje se protutijelo ili antigen-vezujući fragment daju zajedno s RITUXAN-om.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15894209P | 2009-03-10 | 2009-03-10 | |
| US16292409P | 2009-03-24 | 2009-03-24 | |
| EP10708865.0A EP2406284B9 (en) | 2009-03-10 | 2010-03-10 | Anti-bcma antibodies |
| PCT/US2010/026825 WO2010104949A2 (en) | 2009-03-10 | 2010-03-10 | Anti-bcma antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20161194T1 true HRP20161194T1 (hr) | 2016-11-04 |
Family
ID=42139515
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20161194TT HRP20161194T1 (hr) | 2009-03-10 | 2016-09-19 | Anti-bcma protutijela |
Country Status (21)
| Country | Link |
|---|---|
| US (5) | US9034324B2 (hr) |
| EP (2) | EP2406284B9 (hr) |
| JP (2) | JP6061469B2 (hr) |
| KR (1) | KR101589785B1 (hr) |
| CN (2) | CN102421801B (hr) |
| AU (2) | AU2010224160A1 (hr) |
| CA (1) | CA2754938C (hr) |
| CY (1) | CY1118069T1 (hr) |
| DK (1) | DK2406284T5 (hr) |
| ES (1) | ES2593583T3 (hr) |
| HK (1) | HK1166333A1 (hr) |
| HR (1) | HRP20161194T1 (hr) |
| HU (1) | HUE029619T4 (hr) |
| IL (1) | IL214996A (hr) |
| LT (1) | LT2406284T (hr) |
| MX (2) | MX341884B (hr) |
| NZ (2) | NZ594985A (hr) |
| PL (1) | PL2406284T3 (hr) |
| PT (1) | PT2406284T (hr) |
| SI (1) | SI2406284T1 (hr) |
| WO (1) | WO2010104949A2 (hr) |
Families Citing this family (213)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009132058A2 (en) * | 2008-04-25 | 2009-10-29 | Zymogenetics, Inc. | Levels of bcma protein expression on b cells and use in diagnostic methods |
| US20130273055A1 (en) * | 2010-11-16 | 2013-10-17 | Eric Borges | Agents and methods for treating diseases that correlate with bcma expression |
| US20130101599A1 (en) * | 2011-04-21 | 2013-04-25 | Boehringer Ingelheim International Gmbh | Bcma-based stratification and therapy for multiple myeloma patients |
| CN107936121B (zh) | 2011-05-16 | 2022-01-14 | 埃泰美德(香港)有限公司 | 多特异性fab融合蛋白及其使用方法 |
| DK3415531T3 (da) * | 2011-05-27 | 2023-09-18 | Glaxo Group Ltd | Bcma (cd269/tnfrsf17)-bindende proteiner |
| UA112434C2 (uk) | 2011-05-27 | 2016-09-12 | Ґлаксо Ґруп Лімітед | Антигензв'язувальний білок, який специфічно зв'язується з всма |
| TWI679212B (zh) | 2011-11-15 | 2019-12-11 | 美商安進股份有限公司 | 針對ｂｃｍａ之e3以及ｃｄ３的結合分子 |
| KR102229945B1 (ko) * | 2012-04-11 | 2021-03-18 | 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 | B-세포 성숙 항원을 표적화하는 키메라 항원 수용체 |
| JP6694712B2 (ja) * | 2012-11-01 | 2020-05-20 | マックス−デルブルック−セントラム フアー モレキュラーレ メデジン | Ｃｄ２６９（ｂｃｍａ）に対する抗体 |
| AU2013204922B2 (en) | 2012-12-20 | 2015-05-14 | Celgene Corporation | Chimeric antigen receptors |
| EP2762497A1 (en) | 2013-02-05 | 2014-08-06 | EngMab AG | Bispecific antibodies against CD3epsilon and BCMA |
| EP2762496A1 (en) | 2013-02-05 | 2014-08-06 | EngMab AG | Method for the selection of antibodies against BCMA |
| WO2014122144A1 (en) | 2013-02-05 | 2014-08-14 | Engmab Ag | BISPECIFIC ANTIBODIES AGAINST CD3ε AND BCMA |
| WO2014152177A1 (en) | 2013-03-15 | 2014-09-25 | Anthrogenesis Corporation | Modified t lymphocytes |
| AR095374A1 (es) | 2013-03-15 | 2015-10-14 | Amgen Res (Munich) Gmbh | Moléculas de unión para bcma y cd3 |
| ES2959480T3 (es) | 2014-02-07 | 2024-02-26 | Univ Mcmaster | Acoplador de células T - antígeno trifuncional y métodos y usos del mismo |
| JP6825910B2 (ja) | 2014-03-26 | 2021-02-03 | ヘルムホルツ・ツェントルム・ミュンヒェン・ドイチェス・フォルシュンクスツェントルム・フューア・ゲズントハイト・ウント・ウムベルト（ゲーエムベーハー）Ｈｅｌｍｈｏｌｔｚ Ｚｅｎｔｒｕｍ Ｍｕｅｎｃｈｅｎ Ｄｅｕｔｓｃｈｅｓ Ｆｏｒｓｃｈｕｎｇｓｚｅｎｔｒｕｍ ｆｕｅｒ Ｇｅｓｕｎｄｈｅｉｔ ｕｎｄ Ｕｍｗｅｌｔ （ＧｍｂＨ） | Ｆｌａｔｔｏｐ（Ｆｌｔｐ）はβ細胞成熟についての新規のバイオマーカーである |
| BR112016024481A2 (pt) | 2014-04-25 | 2017-10-10 | Bluebird Bio Inc | receptores quiméricos de antígenos com promotor mnd |
| AU2015254526B2 (en) * | 2014-04-30 | 2020-04-30 | Max-Delbruck-Centrum Fur Molekulare Medizin In Der Helmholtz-Gemeinschaft | Humanized antibodies against CD269 (BCMA) |
| SI3151672T1 (sl) | 2014-06-06 | 2021-03-31 | Bluebird Bio, Inc. | Izboljšani T-celični sestavki |
| EP3172237A2 (en) | 2014-07-21 | 2017-05-31 | Novartis AG | Treatment of cancer using humanized anti-bcma chimeric antigen receptor |
| KR102524920B1 (ko) | 2014-07-22 | 2023-04-25 | 아폴로믹스 인코포레이티드 | 항-pd-1 항체 |
| SG10201900455YA (en) * | 2014-07-24 | 2019-02-27 | Bluebird Bio Inc | Bcma chimeric antigen receptors |
| EP2982692A1 (en) | 2014-08-04 | 2016-02-10 | EngMab AG | Bispecific antibodies against CD3epsilon and BCMA |
| EP3177649B1 (en) | 2014-08-05 | 2024-02-28 | Apollomics Inc. | Anti-pd-l1 antibodies |
| EP3023437A1 (en) | 2014-11-20 | 2016-05-25 | EngMab AG | Bispecific antibodies against CD3epsilon and BCMA |
| EP3029068A1 (en) | 2014-12-03 | 2016-06-08 | EngMab AG | Bispecific antibodies against CD3epsilon and BCMA for use in the treatment of diseases |
| PT3226897T (pt) | 2014-12-05 | 2021-04-13 | Eureka Therapeutics Inc | Anticorpos tendo como alvo o antigénio de maturação das células b e métodos de utilização |
| PL3227432T3 (pl) | 2014-12-05 | 2024-03-11 | Memorial Sloan Kettering Cancer Center | Chimeryczne receptory antygenowe ukierunkowane na antygen dojrzewania komórek b i ich zastosowania |
| BR112017012502B1 (pt) | 2014-12-12 | 2020-09-15 | Bluebird Bio, Inc. | Polinucleotídeo, polipeptídeo de car codificado pelo dito polinucleotídeo, vetor compreendendo o dito polinucleotídeo, composição compreendendo o dito vetor e método para geração de uma célula imune efetora compreendendo um car |
| JP6913025B2 (ja) * | 2015-04-13 | 2021-08-04 | ファイザー・インク | 治療抗体およびその使用 |
| IL297223A (en) | 2015-04-13 | 2022-12-01 | Pfizer | Chimeric antigen receptors antigen-directed maturation of b cells |
| HUE051661T2 (hu) * | 2015-05-18 | 2021-03-29 | Tcr2 Therapeutics Inc | Készítmények és gyógyászati felhasználások a TCR újraprogramozására fúziós fehérjék felhasználásával |
| CN116808219A (zh) * | 2015-07-24 | 2023-09-29 | 安可初克公司 | 用于治疗免疫***功能障碍的γ分泌酶调节剂 |
| TWI829617B (zh) | 2015-07-31 | 2024-01-21 | 德商安美基研究（慕尼黑）公司 | Ｆｌｔ３及ｃｄ３抗體構築體 |
| TWI796283B (zh) | 2015-07-31 | 2023-03-21 | 德商安美基研究（慕尼黑）公司 | Ｍｓｌｎ及ｃｄ３抗體構築體 |
| PT3331910T (pt) | 2015-08-03 | 2020-03-24 | Engmab Sarl | Anticorpos monoclonais contra o antigénio de maturação de células b (bcma) humano |
| PL3337824T3 (pl) | 2015-08-17 | 2021-04-19 | Janssen Pharmaceutica Nv | Przeciwciała anty-bcma, bispecyficzne cząsteczki wiążące antygen, które wiążą bcma i cd3, oraz ich zastosowania |
| WO2017058850A1 (en) | 2015-09-28 | 2017-04-06 | Regents Of The University Of Minnesota | Chimeric antigen receptor (car) t cells as therapeutic interventions for auto- and allo-immunity |
| CN108473575B (zh) * | 2015-11-13 | 2022-04-19 | 美国卫生和人力服务部 | 抗-bcma多肽和蛋白质 |
| US11479755B2 (en) | 2015-12-07 | 2022-10-25 | 2Seventy Bio, Inc. | T cell compositions |
| DK3402515T3 (da) | 2016-01-12 | 2021-11-15 | Oncotracker Inc | Forbedrede fremgangsmåder til monitorering af et individs immunstatus |
| KR20180101623A (ko) | 2016-02-03 | 2018-09-12 | 암젠 리서치 (뮌헨) 게엠베하 | Psma 및 cd3 이중특이성 t 세포 맞물림 항체 작제물 |
| EA039859B1 (ru) | 2016-02-03 | 2022-03-21 | Эмджен Рисерч (Мюник) Гмбх | Биспецифические конструкты антител, связывающие egfrviii и cd3 |
| EP3411402B1 (en) * | 2016-02-03 | 2021-12-22 | Amgen Research (Munich) GmbH | Bcma and cd3 bispecific t cell engaging antibody constructs |
| MX2018009700A (es) * | 2016-02-17 | 2019-01-24 | Seattle Genetics Inc | Anticuerpos contra bcma y su uso para tratar el cancer y los trastornos inmunitarios. |
| US20200281973A1 (en) | 2016-03-04 | 2020-09-10 | Novartis Ag | Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore |
| WO2017157305A1 (en) | 2016-03-15 | 2017-09-21 | Generon (Shanghai) Corporation Ltd. | Multispecific fab fusion proteins and use thereof |
| MA43603A1 (fr) | 2016-04-01 | 2019-03-29 | Amgen Inc | Récepteurs chimériques et leurs procédés d'utilisation |
| IL303785A (en) | 2016-04-01 | 2023-08-01 | Kite Pharma Inc | Chimeric antigen and T cell receptors and methods of use |
| NZ746700A (en) | 2016-04-01 | 2023-04-28 | Kite Pharma Inc | Bcma binding molecules and methods of use thereof |
| CN109641049B (zh) | 2016-06-21 | 2023-07-07 | 特尼奥生物股份有限公司 | Cd3结合抗体 |
| JP7109789B2 (ja) | 2016-08-02 | 2022-08-01 | ティーシーアール２ セラピューティクス インク． | 融合タンパク質を使用したｔｃｒの再プログラム化のための組成物及び方法 |
| CR20220578A (es) | 2016-09-14 | 2023-01-17 | Teneobio Inc | Anticuerpos de unión a cd3 |
| ES2875959T3 (es) | 2016-10-07 | 2021-11-11 | Tcr2 Therapeutics Inc | Composiciones y métodos para reprogramación de receptores de linfocitos T mediante el uso de proteínas de fusión |
| EP4295918A3 (en) | 2016-11-02 | 2024-03-20 | Bristol-Myers Squibb Company | Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myeloma |
| WO2018098365A2 (en) | 2016-11-22 | 2018-05-31 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| BR112019012354A2 (pt) | 2016-12-21 | 2019-11-26 | Teneobio Inc | anticorpos apenas de cadeia pesada anti-bcma |
| WO2018144535A1 (en) | 2017-01-31 | 2018-08-09 | Novartis Ag | Treatment of cancer using chimeric t cell receptor proteins having multiple specificities |
| AU2018222749B2 (en) | 2017-02-17 | 2024-04-18 | Fred Hutchinson Cancer Center | Combination therapies for treatment of BCMA-related cancers and autoimmune disorders |
| AU2018228719B2 (en) | 2017-02-28 | 2023-03-30 | Affimed Gmbh | Tandem diabody for CD16A-directed NK-cell engagement |
| EP3604340A4 (en) | 2017-03-24 | 2021-01-06 | Zenyaku Kogyo Co., Ltd | ANTI-IGM / B-CELL SURFACE ANTIGEN-BISPECIFIC ANTIBODY |
| EP3615068A1 (en) | 2017-04-28 | 2020-03-04 | Novartis AG | Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor |
| US20200055948A1 (en) | 2017-04-28 | 2020-02-20 | Novartis Ag | Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor |
| WO2018204427A1 (en) | 2017-05-01 | 2018-11-08 | Juno Therapeutics, Inc. | Combination of a cell therapy and an immunomodulatory compound |
| US11635435B2 (en) | 2017-06-13 | 2023-04-25 | Oncotracker, Inc. | Diagnostic, prognostic, and monitoring methods for solid tumor cancers |
| CA3063598A1 (en) | 2017-06-14 | 2018-12-20 | Dana-Farber Cancer Institute, Inc. | B-cell maturation antigen (bcma)-directed nanoparticles |
| JP7303126B2 (ja) | 2017-06-20 | 2023-07-04 | テネオバイオ， インコーポレイテッド | 抗ｂｃｍａ重鎖のみ抗体 |
| US11427642B2 (en) | 2017-06-20 | 2022-08-30 | Teneoone, Inc. | Anti-BCMA heavy chain-only antibodies |
| WO2019000223A1 (en) | 2017-06-27 | 2019-01-03 | Nanjing Legend Biotech Co., Ltd. | ENABLERS OF IMMUNE EFFECTOR CELLS OF CHIMERIC ANTIBODIES AND METHODS OF USE THEREOF |
| MA51447A (fr) | 2017-08-01 | 2020-06-10 | Medimmune Llc | Conjugué anticorps monoclonal-médicament dirigé contre bcma |
| WO2019035938A1 (en) | 2017-08-16 | 2019-02-21 | Elstar Therapeutics, Inc. | MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF |
| CN111133007A (zh) | 2017-09-13 | 2020-05-08 | 特尼奥生物股份有限公司 | 与胞外酶结合的重链抗体 |
| JP7137619B2 (ja) * | 2017-09-29 | 2022-09-14 | モガム・インスティテュート・フォー・バイオメディカル・リサーチ | Ｂｃｍａに対して高い親和性を有する抗ｂｃｍａ抗体およびそれを含むがんの処置のための医薬組成物 |
| EP3694997A4 (en) | 2017-10-12 | 2021-06-30 | Mcmaster University | T-CELL ANTIGEN COUPLER WITH Y182T MUTATION, AND PROCEDURES AND USES THEREOF |
| WO2019079569A1 (en) | 2017-10-18 | 2019-04-25 | Novartis Ag | COMPOSITIONS AND METHODS FOR SELECTIVE DEGRADATION OF A PROTEIN |
| KR20200074997A (ko) | 2017-11-01 | 2020-06-25 | 주노 쎄러퓨티크스 인코퍼레이티드 | B-세포 성숙 항원에 특이적인 항체 및 키메릭 항원 수용체 |
| MX2020004572A (es) | 2017-11-01 | 2020-10-07 | Juno Therapeutics Inc | Receptores de antigenos quimericos especificos para el antigeno de maduracion de celulas b y polinucleotidos que codifican los mismos. |
| BR112020008812A2 (pt) | 2017-11-06 | 2020-10-27 | Juno Therapeutics Inc | combinação de terapia celular e um inibidor de gama secretase |
| WO2019099639A1 (en) | 2017-11-15 | 2019-05-23 | Navartis Ag | Bcma-targeting chimeric antigen receptor, cd19-targeting chimeric antigen receptor, and combination therapies |
| MX2020005651A (es) | 2017-11-30 | 2020-10-28 | Novartis Ag | Receptor de antigeno quimerico dirigido a bcma y usos del mismo. |
| JP2021505168A (ja) | 2017-12-08 | 2021-02-18 | ジュノー セラピューティクス インコーポレイテッド | 操作されたｔ細胞の組成物を製造するための方法 |
| CN112041430A (zh) | 2017-12-08 | 2020-12-04 | 朱诺治疗学股份有限公司 | 用于培养细胞的无血清培养基配制品及其使用方法 |
| AU2018392088A1 (en) | 2017-12-22 | 2020-08-13 | Teneobio, Inc. | Heavy chain antibodies binding to CD22 |
| US20200368268A1 (en) | 2018-01-08 | 2020-11-26 | Novartis Ag | Immune-enhancing rnas for combination with chimeric antigen receptor therapy |
| AU2019215031A1 (en) | 2018-01-31 | 2020-08-20 | Novartis Ag | Combination therapy using a chimeric antigen receptor |
| US11807663B2 (en) | 2018-02-01 | 2023-11-07 | Innovent Biologics (Suzhou) Co., Ltd. | Fully humanized anti-B cell maturation antigen (BCMA) single-chain antibody and use thereof |
| CN116082518A (zh) | 2018-02-01 | 2023-05-09 | 南京驯鹿生物技术股份有限公司 | 一种结合bcma的嵌合抗原受体（car）及其应用 |
| EP3674327A4 (en) | 2018-02-01 | 2021-05-05 | Nanjing Iaso Biotherapeutics Co., Ltd. | CHEMICAL ANTIGENIC RECEPTOR (CAR) BINDING TO BCMA AND ITS APPLICATIONS |
| WO2019160956A1 (en) | 2018-02-13 | 2019-08-22 | Novartis Ag | Chimeric antigen receptor therapy in combination with il-15r and il15 |
| WO2019166650A1 (en) | 2018-03-02 | 2019-09-06 | Cdr-Life Ag | Trispecific antigen binding proteins |
| CN113817066A (zh) | 2018-04-13 | 2021-12-21 | 艾菲默德有限责任公司 | 自然杀伤细胞接合抗体融合构建体 |
| WO2019226658A1 (en) | 2018-05-21 | 2019-11-28 | Compass Therapeutics Llc | Multispecific antigen-binding compositions and methods of use |
| CA3098420A1 (en) | 2018-06-01 | 2019-12-05 | Novartis Ag | Binding molecules against bcma and uses thereof |
| JP7438988B2 (ja) | 2018-06-13 | 2024-02-27 | ノバルティス アーゲー | Ｂｃｍａキメラ抗原受容体及びその使用 |
| WO2020004934A1 (ko) * | 2018-06-26 | 2020-01-02 | 에이비엘바이오 주식회사 | 항-bcma 항체 및 그 용도 |
| US11845797B2 (en) | 2018-07-03 | 2023-12-19 | Marengo Therapeutics, Inc. | Anti-TCR antibody molecules and uses thereof |
| US11110123B2 (en) | 2018-07-17 | 2021-09-07 | Triumvira Immunologics Usa, Inc. | T cell-antigen coupler with various construct optimizations |
| KR20210034032A (ko) | 2018-07-19 | 2021-03-29 | 리제너론 파아마슈티컬스, 인크. | 이중특이적 항-BCMA x 항-CD3 항체 및 이의 용도 |
| WO2020018922A1 (en) | 2018-07-20 | 2020-01-23 | Teneobio, Inc. | Heavy chain antibodies binding to cd19 |
| KR20210057730A (ko) | 2018-08-09 | 2021-05-21 | 주노 쎄러퓨티크스 인코퍼레이티드 | 조작 세포 및 이의 조성물 생성 방법 |
| SG11202101130VA (en) | 2018-08-09 | 2021-03-30 | Juno Therapeutics Inc | Methods for assessing integrated nucleic acids |
| JP2021534783A (ja) | 2018-08-31 | 2021-12-16 | ノバルティス アーゲー | キメラ抗原受容体発現細胞を作製する方法 |
| WO2020047449A2 (en) | 2018-08-31 | 2020-03-05 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
| WO2020087065A1 (en) | 2018-10-26 | 2020-04-30 | Teneobio, Inc. | Heavy chain antibodies binding to cd38 |
| SG11202104355SA (en) | 2018-10-31 | 2021-05-28 | Juno Therapeutics Gmbh | Methods for selection and stimulation of cells and apparatus for same |
| PE20211058A1 (es) | 2018-11-01 | 2021-06-07 | Juno Therapeutics Inc | Receptores de antigenos quimericos especificos para el miembro d del grupo 5 de la clase c del receptor acoplado a proteina g (gprc5d) |
| EP3873943A2 (en) | 2018-11-01 | 2021-09-08 | Juno Therapeutics, Inc. | Methods for treatment using chimeric antigen receptors specific for b-cell maturation antigen |
| CN113573719A (zh) | 2018-11-08 | 2021-10-29 | 朱诺治疗学股份有限公司 | 治疗和t细胞调节的方法和组合 |
| SG11202009283QA (en) | 2019-01-16 | 2020-10-29 | Caribou Biosciences Inc | Humanized bcma antibody and bcma-car-t cells |
| KR20210134339A (ko) | 2019-02-25 | 2021-11-09 | 노파르티스 아게 | 바이러스 전달을 위한 메조다공성 실리카 입자 조성물 |
| EP3942025A1 (en) | 2019-03-21 | 2022-01-26 | Novartis AG | Car-t cell therapies with enhanced efficacy |
| BR112021019334A2 (pt) | 2019-04-05 | 2021-12-07 | Teneobio Inc | Anticorpos de cadeia pesada que se ligam ao psma |
| US20220168389A1 (en) | 2019-04-12 | 2022-06-02 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
| WO2020219742A1 (en) | 2019-04-24 | 2020-10-29 | Novartis Ag | Compositions and methods for selective protein degradation |
| EP3967329A4 (en) | 2019-05-07 | 2023-06-14 | Gracell Biotechnologies (Shanghai) Co., Ltd. | AGAINST BCMA GM IMMUNE CELLS AND THEIR USE |
| WO2020224605A1 (zh) | 2019-05-07 | 2020-11-12 | 亘喜生物科技（上海）有限公司 | 靶向bcma的工程化免疫细胞及其用途 |
| AU2020291938A1 (en) | 2019-06-14 | 2022-01-20 | Teneobio, Inc. | Multispecific heavy chain antibodies binding to CD22 and CD3 |
| CN112585168B (zh) * | 2019-07-30 | 2022-04-15 | 上海翰森生物医药科技有限公司 | 抗bcma抗体、其抗原结合片段及其医药用途 |
| US20230374130A1 (en) | 2019-07-30 | 2023-11-23 | Qlsf Biotherapeutics, Inc. | Bispecific anti lrrc15 and cd3epsilon antibodies |
| CN112409482B (zh) * | 2019-08-20 | 2022-08-26 | 杭州尚健生物技术有限公司 | Bcma抗体 |
| US20220331363A1 (en) * | 2019-09-20 | 2022-10-20 | Shanghai GenBase Biotechnology Co., Ltd. | Bcma-targeted antibody and chimeric antigen receptor |
| WO2021108661A2 (en) | 2019-11-26 | 2021-06-03 | Novartis Ag | Chimeric antigen receptors and uses thereof |
| WO2021132746A1 (en) * | 2019-12-24 | 2021-07-01 | Abl Bio, Inc. | Anti-bcma/anti-4-1bb bispecific antibodies and uses thereof |
| JP2023507120A (ja) | 2019-12-18 | 2023-02-21 | テネオフォー， インコーポレイテッド | Ｃｄ３８に結合する重鎖抗体 |
| KR20220012314A (ko) * | 2020-01-03 | 2022-02-03 | 살루브리스 (청두) 바이오테크 코., 리미티드 | Bcma에 결합하는 항체 및 그의 용도 |
| CA3166420A1 (en) | 2020-01-14 | 2021-07-22 | Synthekine, Inc. | Il2 orthologs and methods of use |
| CN111234020B (zh) * | 2020-01-23 | 2020-10-23 | 和铂医药(苏州)有限公司 | 一种bcma结合蛋白及其制备方法和应用 |
| WO2021154887A1 (en) | 2020-01-28 | 2021-08-05 | Juno Therapeutics, Inc. | Methods for t cell transduction |
| KR20220152227A (ko) | 2020-02-12 | 2022-11-15 | 주노 쎄러퓨티크스 인코퍼레이티드 | Ｂｃｍａ-지시된 키메라 항원 수용체 ｔ 세포 조성물 및 이의 방법 및 용도 |
| CN113248611A (zh) * | 2020-02-13 | 2021-08-13 | 湖南华康恒健生物技术有限公司 | 抗bcma抗体、其药物组合物及应用 |
| TW202146441A (zh) | 2020-02-27 | 2021-12-16 | 瑞士商諾華公司 | 製備表現嵌合抗原受體的細胞之方法 |
| WO2021173995A2 (en) | 2020-02-27 | 2021-09-02 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
| BR112022020333A2 (pt) | 2020-04-10 | 2022-11-22 | Juno Therapeutics Inc | Métodos e usos relacionados à terapia celular projetada com um receptor de antígeno quimérico que alveja o antígeno de maturação de células b |
| CN116157125A (zh) | 2020-04-28 | 2023-05-23 | 朱诺治疗学股份有限公司 | 针对bcma的t细胞疗法与免疫调节化合物的组合 |
| TW202330622A (zh) | 2020-04-29 | 2023-08-01 | 美商泰尼歐生物公司 | 具有經修飾重鏈恆定區之多特異性重鏈抗體 |
| EP4121172A1 (en) | 2020-04-29 | 2023-01-25 | Teneobio, Inc. | Multispecific heavy chain antibodies with modified heavy chain constant regions |
| IL298046A (en) | 2020-05-11 | 2023-01-01 | Janssen Biotech Inc | Treatment methods for multiple myeloma |
| US20230178239A1 (en) | 2020-05-13 | 2023-06-08 | Juno Therapeutics, Inc. | Methods of identifying features associated with clinical response and uses thereof |
| JP2023529211A (ja) | 2020-06-11 | 2023-07-07 | ノバルティス アーゲー | Ｚｂｔｂ３２阻害剤及びその使用 |
| CR20220656A (es) | 2020-06-30 | 2023-03-01 | Teneobio Inc | Unión de anticuerpos multiespecíficos a bcma |
| WO2022035793A1 (en) | 2020-08-10 | 2022-02-17 | Precision Biosciences, Inc. | Antibodies and fragments specific for b-cell maturation antigen and uses thereof |
| JP2023539453A (ja) * | 2020-08-20 | 2023-09-14 | チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド | Ｂｃｍａと結合する単一可変ドメイン及び抗原結合分子 |
| CA3188978A1 (en) | 2020-08-21 | 2022-02-24 | Sandeep Tharian Koshy | Compositions and methods for in vivo generation of car expressing cells |
| WO2022060806A1 (en) | 2020-09-16 | 2022-03-24 | Obsidian Therapeutics, Inc. | Compositions and methods for expression of anti-bcma chimeric antigen receptors with small molecule-regulated il15 in t cells |
| EP4229094A1 (en) | 2020-10-16 | 2023-08-23 | QLSF Biotherapeutics, Inc. | Multispecific binding compounds that bind to pd-l1 |
| WO2022094245A1 (en) | 2020-10-30 | 2022-05-05 | Vor Biopharma, Inc. | Compositions and methods for bcma modification |
| US20230398148A1 (en) | 2020-11-04 | 2023-12-14 | Juno Therapeutics, Inc. | Cells expressing a chimeric receptor from a modified invariant cd3 immunoglobulin superfamily chain locus and related polynucleotides and methods |
| TW202233684A (zh) | 2020-11-18 | 2022-09-01 | 美商泰尼歐生物公司 | 結合於葉酸受體α之重鏈抗體 |
| JP2024501971A (ja) | 2020-12-31 | 2024-01-17 | サナ バイオテクノロジー，インコーポレイテッド | Ｃａｒ－ｔ活性を調節するための方法及び組成物 |
| CN113024671B (zh) * | 2020-12-31 | 2022-05-24 | 北京艺妙神州医药科技有限公司 | 一种抗bcma的抗体及其应用 |
| CA3204161A1 (en) | 2021-01-11 | 2022-07-14 | Jagesh Vijaykumar SHAH | Use of cd8-targeted viral vectors |
| CN117279953A (zh) | 2021-02-16 | 2023-12-22 | 詹森药业有限公司 | 靶向bcma、gprc5d和cd3的三特异性抗体 |
| CA3211138A1 (en) | 2021-02-25 | 2022-09-01 | Teneobio, Inc. | Anti-psma antibodies and car-t structures |
| AU2022226565A1 (en) | 2021-02-26 | 2023-08-31 | Teneobio, Inc. | Anti-muc1-c antibodies and car-t structures |
| KR20230165771A (ko) | 2021-03-03 | 2023-12-05 | 주노 쎄러퓨티크스 인코퍼레이티드 | T 세포 요법 및 dgk 억제제의 조합 |
| CA3212343A1 (en) | 2021-03-17 | 2022-09-22 | Kazunori YOSHIKIYO | Gene encoding a chimeric receptor for an anti-acetylcholine receptor autoantibody |
| CN117321417A (zh) | 2021-03-22 | 2023-12-29 | 朱诺治疗学股份有限公司 | 确定治疗性细胞组合物的效力的方法 |
| WO2022204071A1 (en) | 2021-03-22 | 2022-09-29 | Juno Therapeutics, Inc. | Method to assess potency of viral vector particles |
| TW202304994A (zh) | 2021-04-02 | 2023-02-01 | 美商泰尼歐生物公司 | 促效性抗ｉｌ－２ｒ抗體及使用方法 |
| WO2022216864A1 (en) | 2021-04-06 | 2022-10-13 | Teneobio, Inc. | Anti-cd19 antibodies and car-t structures |
| GB2623199A (en) | 2021-04-08 | 2024-04-10 | Marengo Therapeutics Inc | Multifunctional molecules binding to TCR and uses thereof |
| IL307598A (en) | 2021-04-16 | 2023-12-01 | Juno Therapeutics Inc | T-cell therapy in patients who have had a previous stem cell transplant |
| WO2022221726A2 (en) | 2021-04-16 | 2022-10-20 | Juno Therapeutics, Inc. | Combination therapies with bcma-directed t cell therapy |
| AU2022259688A1 (en) | 2021-04-16 | 2023-10-05 | Teneobio, Inc. | Anti-cd20 antibodies and car-t structures |
| CN118056008A (zh) | 2021-04-27 | 2024-05-17 | 诺华股份有限公司 | 病毒载体生产*** |
| CN117916256A (zh) | 2021-05-06 | 2024-04-19 | 朱诺治疗学有限公司 | 用于刺激和转导t细胞的方法 |
| TW202309522A (zh) | 2021-05-11 | 2023-03-01 | 美商健生生物科技公司 | 用於監測復發性及／或難治性多發性骨髓瘤之治療的方法及組成物 |
| WO2022246293A1 (en) | 2021-05-19 | 2022-11-24 | Sana Biotechnology, Inc. | Hypoimmunogenic rhd negative primary t cells |
| WO2022251367A1 (en) | 2021-05-27 | 2022-12-01 | Sana Biotechnology, Inc. | Hypoimmunogenic cells comprising engineered hla-e or hla-g |
| WO2022271987A1 (en) | 2021-06-23 | 2022-12-29 | TeneoFour, Inc. | Anti-cd38 antibodies and epitopes of same |
| US11453723B1 (en) | 2021-06-25 | 2022-09-27 | Mcmaster University | BCMA T cell-antigen couplers and uses thereof |
| EP4362957A1 (en) | 2021-07-01 | 2024-05-08 | Indapta Therapeutics, Inc. | Engineered natural killer (nk) cells and related methods |
| KR20240046319A (ko) | 2021-07-14 | 2024-04-08 | 사나 바이오테크놀로지, 인크. | 저면역원성 세포에서의 y 염색체-연결 항원의 변경된 발현 |
| AU2022310862A1 (en) | 2021-07-14 | 2024-02-01 | Regeneron Pharmaceuticals, Inc. | Engineered t cell receptors fused to binding domains from antibodies |
| WO2023004197A1 (en) | 2021-07-23 | 2023-01-26 | Teneoten, Inc. | Heavy chain antibodies binding to hepatitis b surface antigen |
| WO2023015217A1 (en) | 2021-08-04 | 2023-02-09 | Sana Biotechnology, Inc. | Use of cd4-targeted viral vectors |
| KR20240053673A (ko) | 2021-08-11 | 2024-04-24 | 사나 바이오테크놀로지, 인크. | 저면역원성 세포 내 유전자 발현을 변경하기 위한 유도성 시스템 |
| AU2022330406A1 (en) | 2021-08-20 | 2024-03-07 | Novartis Ag | Methods of making chimeric antigen receptor–expressing cells |
| US20230192843A1 (en) | 2021-10-14 | 2023-06-22 | Teneobio, Inc. | Mesothelin binding proteins and uses thereof |
| WO2023069790A1 (en) | 2021-10-22 | 2023-04-27 | Sana Biotechnology, Inc. | Methods of engineering allogeneic t cells with a transgene in a tcr locus and associated compositions and methods |
| WO2023081735A1 (en) | 2021-11-03 | 2023-05-11 | Celgene Corporation | Chimeric antigen receptors specific for b-cell maturation antigen for use in treating myeloma |
| WO2023115039A2 (en) | 2021-12-17 | 2023-06-22 | Sana Biotechnology, Inc. | Modified paramyxoviridae fusion glycoproteins |
| WO2023115041A1 (en) | 2021-12-17 | 2023-06-22 | Sana Biotechnology, Inc. | Modified paramyxoviridae attachment glycoproteins |
| WO2023122337A1 (en) | 2021-12-23 | 2023-06-29 | Sana Biotechnology, Inc. | Chimeric antigen receptor (car) t cells for treating autoimmune disease and associated methods |
| CN114276452A (zh) * | 2021-12-29 | 2022-04-05 | 源道隆（苏州）医学科技有限公司 | 可结合bcma的纳米抗体及其应用 |
| TW202334400A (zh) | 2021-12-30 | 2023-09-01 | 美商Ｔｒ１Ｘ股份有限公司 | 表現il-10及嵌合抗原受體之cd4+ t細胞及其用途 |
| WO2023133595A2 (en) | 2022-01-10 | 2023-07-13 | Sana Biotechnology, Inc. | Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses |
| WO2023147515A1 (en) | 2022-01-28 | 2023-08-03 | Juno Therapeutics, Inc. | Methods of manufacturing cellular compositions |
| WO2023150518A1 (en) | 2022-02-01 | 2023-08-10 | Sana Biotechnology, Inc. | Cd3-targeted lentiviral vectors and uses thereof |
| WO2023150647A1 (en) | 2022-02-02 | 2023-08-10 | Sana Biotechnology, Inc. | Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses |
| WO2023152747A1 (en) | 2022-02-09 | 2023-08-17 | Hadasit Medical Research Services And Development Ltd. | Anti-bcma car to target immune-related disorders, compositions and method thereof |
| WO2023158836A1 (en) | 2022-02-17 | 2023-08-24 | Sana Biotechnology, Inc. | Engineered cd47 proteins and uses thereof |
| WO2023193015A1 (en) | 2022-04-01 | 2023-10-05 | Sana Biotechnology, Inc. | Cytokine receptor agonist and viral vector combination therapies |
| WO2023196996A2 (en) | 2022-04-08 | 2023-10-12 | 2Seventy Bio, Inc. | Multipartite receptor and signaling complexes |
| WO2023215725A1 (en) | 2022-05-02 | 2023-11-09 | Fred Hutchinson Cancer Center | Compositions and methods for cellular immunotherapy |
| WO2023213969A1 (en) | 2022-05-05 | 2023-11-09 | Juno Therapeutics Gmbh | Viral-binding protein and related reagents, articles, and methods of use |
| WO2023220641A2 (en) | 2022-05-11 | 2023-11-16 | Juno Therapeutics, Inc. | Methods and uses related to t cell therapy and production of same |
| WO2023220655A1 (en) | 2022-05-11 | 2023-11-16 | Celgene Corporation | Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy |
| WO2023230548A1 (en) | 2022-05-25 | 2023-11-30 | Celgene Corporation | Method for predicting response to a t cell therapy |
| WO2023230581A1 (en) | 2022-05-25 | 2023-11-30 | Celgene Corporation | Methods of manufacturing t cell therapies |
| WO2024007020A1 (en) | 2022-06-30 | 2024-01-04 | Indapta Therapeutics, Inc. | Combination of engineered natural killer (nk) cells and antibody therapy and related methods |
| WO2024026358A1 (en) | 2022-07-27 | 2024-02-01 | Teneobio, Inc. | Mesothelin binding proteins and uses thereof |
| WO2024026377A1 (en) | 2022-07-27 | 2024-02-01 | Sana Biotechnology, Inc. | Methods of transduction using a viral vector and inhibitors of antiviral restriction factors |
| EP4311579A1 (en) * | 2022-07-29 | 2024-01-31 | Association Française contre les Myopathies | B cell-specific mab-sirna conjugates improve myasthenia |
| WO2024031091A2 (en) | 2022-08-05 | 2024-02-08 | Juno Therapeutics, Inc. | Chimeric antigen receptors specific for gprc5d and bcma |
| WO2024054944A1 (en) | 2022-09-08 | 2024-03-14 | Juno Therapeutics, Inc. | Combination of a t cell therapy and continuous or intermittent dgk inhibitor dosing |
| WO2024064838A1 (en) | 2022-09-21 | 2024-03-28 | Sana Biotechnology, Inc. | Lipid particles comprising variant paramyxovirus attachment glycoproteins and uses thereof |
| WO2024077044A1 (en) | 2022-10-05 | 2024-04-11 | Amgen Inc. | Combination therapies comprising t-cell redirecting therapies and agonistic anti-il-2r antibodies or fragments thereof |
| WO2024081820A1 (en) | 2022-10-13 | 2024-04-18 | Sana Biotechnology, Inc. | Viral particles targeting hematopoietic stem cells |
| WO2024089639A1 (en) | 2022-10-26 | 2024-05-02 | Novartis Ag | Lentiviral formulations |
| WO2024097905A1 (en) | 2022-11-02 | 2024-05-10 | Celgene Corporation | Methods of treatment with t cell therapy and immunomodulatory agent maintenance therapy |
| WO2024100604A1 (en) | 2022-11-09 | 2024-05-16 | Juno Therapeutics Gmbh | Methods for manufacturing engineered immune cells |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| WO1993006217A1 (en) | 1991-09-19 | 1993-04-01 | Genentech, Inc. | EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES |
| US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| CN101518648A (zh) | 1999-01-07 | 2009-09-02 | 津莫吉尼蒂克斯公司 | 可溶性受体br43×2和应用方法 |
| US7833529B1 (en) | 1999-01-07 | 2010-11-16 | Zymogenetics, Inc. | Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor |
| US20060067933A1 (en) | 1999-01-07 | 2006-03-30 | Gross Jane A | Soluble receptor BR43x2 and methods of using |
| WO2000068378A1 (en) | 1999-05-06 | 2000-11-16 | National Jewish Medical And Research Center | Tall-1 nucleic acid molecules, proteins, receptors and methods of use thereof |
| GEP20053685B (en) | 1999-08-17 | 2005-12-12 | Biogen Inc | BAFF Receptor (BCMA), an Immunoregulatory Agent |
| CA2396793A1 (en) | 2000-02-16 | 2001-08-23 | Genentech, Inc. | Uses of agonists and antagonists to modulate activity of tnf-related molecules |
| US20040002068A1 (en) | 2000-03-01 | 2004-01-01 | Corixa Corporation | Compositions and methods for the detection, diagnosis and therapy of hematological malignancies |
| US7371388B1 (en) | 2000-05-04 | 2008-05-13 | Human Genome Sciences, Inc. | Treatment of Sjogren's syndrome by administration of TR18 polypeptides |
| UA83458C2 (uk) | 2000-09-18 | 2008-07-25 | Байоджен Айдек Ма Інк. | Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf) |
| JP2004533997A (ja) | 2001-02-20 | 2004-11-11 | ザイモジェネティクス，インコーポレイティド | Ｂｃｍａ及びｔａｃｉの両者を結合する抗体 |
| CU23007A1 (es) * | 2001-04-06 | 2004-12-17 | Ct De Inmunologia Molecular Ct De Inmunologia Mole | Combinaciones inmunoterapéuticas para el tratamiencombinaciones inmunoterapéuticas para el tratamiento de tumores que sobre-expresan gangliósidos to de tumores que sobre-expresan gangliósidos |
| WO2003013582A1 (en) | 2001-08-06 | 2003-02-20 | Genset S.A. | Genoxit agonists and antagonists for use in the treatment of metabolic disorders |
| AU2003221256A1 (en) * | 2002-02-21 | 2003-09-09 | Biogen Idec Ma Inc. | Use of bcma as an immunoregulatory agent |
| EP1483295B1 (en) | 2002-03-01 | 2008-12-10 | Immunomedics, Inc. | Rs7 antibodies |
| EP2322203A3 (en) | 2002-10-29 | 2011-07-27 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| US20050163775A1 (en) | 2003-06-05 | 2005-07-28 | Genentech, Inc. | Combination therapy for B cell disorders |
| KR20060027801A (ko) | 2003-06-05 | 2006-03-28 | 제넨테크, 인크. | Ｂ 세포 장애에 대한 조합 요법 |
| AU2006281978A1 (en) | 2005-08-12 | 2007-02-22 | Garvan Institute Of Medical Research | Phrophylactic and/or therapeutic method for treatment of autoimmune disease |
| AU2006344395B2 (en) | 2005-10-13 | 2013-05-02 | Human Genome Sciences, Inc. | Methods and compositions for use in treatment of patients with autoantibody positive diseases |
| DOP2006000277A (es) * | 2005-12-12 | 2007-08-31 | Bayer Pharmaceuticals Corp | Anticuerpos anti mn y métodos para su utilización |
| JP2007309746A (ja) * | 2006-05-17 | 2007-11-29 | Osaka Univ | 細胞膜表面物質の結合部位解析方法 |
| WO2008112017A2 (en) | 2006-10-10 | 2008-09-18 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Healtand Human Services | Avian influenza vaccine |
-
2010
- 2010-03-10 NZ NZ59498510A patent/NZ594985A/xx unknown
- 2010-03-10 US US13/255,610 patent/US9034324B2/en active Active
- 2010-03-10 EP EP10708865.0A patent/EP2406284B9/en active Active
- 2010-03-10 AU AU2010224160A patent/AU2010224160A1/en not_active Abandoned
- 2010-03-10 PL PL10708865T patent/PL2406284T3/pl unknown
- 2010-03-10 WO PCT/US2010/026825 patent/WO2010104949A2/en active Application Filing
- 2010-03-10 MX MX2013013076A patent/MX341884B/es unknown
- 2010-03-10 DK DK10708865.0T patent/DK2406284T5/en active
- 2010-03-10 LT LTEP10708865.0T patent/LT2406284T/lt unknown
- 2010-03-10 HU HUE10708865A patent/HUE029619T4/en unknown
- 2010-03-10 PT PT107088650T patent/PT2406284T/pt unknown
- 2010-03-10 KR KR1020117023294A patent/KR101589785B1/ko active IP Right Grant
- 2010-03-10 CN CN201080020559.0A patent/CN102421801B/zh active Active
- 2010-03-10 MX MX2011009430A patent/MX2011009430A/es active IP Right Grant
- 2010-03-10 CN CN201510142069.2A patent/CN104877026B/zh active Active
- 2010-03-10 SI SI201031281A patent/SI2406284T1/sl unknown
- 2010-03-10 CA CA2754938A patent/CA2754938C/en active Active
- 2010-03-10 NZ NZ61264710A patent/NZ612647A/en unknown
- 2010-03-10 JP JP2011554150A patent/JP6061469B2/ja active Active
- 2010-03-10 EP EP16179507.5A patent/EP3141562A1/en not_active Withdrawn
- 2010-03-10 ES ES10708865.0T patent/ES2593583T3/es active Active
-
2011
- 2011-09-06 IL IL214996A patent/IL214996A/en active IP Right Grant
-
2012
- 2012-07-18 HK HK12107062.4A patent/HK1166333A1/zh unknown
-
2014
- 2014-07-16 AU AU2014204447A patent/AU2014204447B2/en active Active
-
2015
- 2015-01-14 US US14/596,769 patent/US20150125460A1/en not_active Abandoned
- 2015-07-09 JP JP2015137493A patent/JP2015187164A/ja active Pending
-
2016
- 2016-03-09 US US15/065,641 patent/US20170029518A1/en not_active Abandoned
- 2016-09-15 CY CY20161100917T patent/CY1118069T1/el unknown
- 2016-09-19 HR HRP20161194TT patent/HRP20161194T1/hr unknown
-
2018
- 2018-07-03 US US16/026,242 patent/US11111307B2/en active Active
-
2021
- 2021-07-30 US US17/444,107 patent/US20220213208A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20161194T1 (hr) | Anti-bcma protutijela | |
| JP2012520308A5 (hr) | ||
| PE20090689A1 (es) | Anticuerpos del antagonista ox40 y su uso en el tratamiento de enfermedades inflamatorias y autoinmunes | |
| HRP20200767T1 (hr) | Humanizirana anti-humana cd19 protutijela i postupci uporabe | |
| HRP20150623T1 (hr) | Monoklonalno protutijelo sposobno za vezivanje na specifiäśni diskontinuirani epitop koji se pojavljuje u podruäśju ad1 od humanog glikoproteina citomegalovirusa gb, te njegov fragment koji se veže na antigen | |
| JP2018513149A5 (hr) | ||
| RU2017123549A (ru) | Антитела, нацеленные на антиген созревания в-клеток, и способы их применения | |
| JP2020510422A5 (hr) | ||
| RU2016100892A (ru) | Антитела против tweakr и их применение | |
| RU2014136332A (ru) | Композиции и способы применения ингибиторов csf1r | |
| JP2019506363A5 (hr) | ||
| HRP20140331T1 (hr) | Optimizirana antitijela usmjerena na cd19 | |
| JP2016511277A5 (hr) | ||
| CN113248614A (zh) | 抗pd-1的人抗体 | |
| HRP20150591T1 (hr) | Smanjenje broja b-stanica koristeä†i cd37-specifiäśne i cd20-specifiäśne vezne molekule | |
| RU2020129387A (ru) | Антитела к pd-1 собак | |
| HRP20220811T1 (hr) | Agonistička sredstva za vezanje tnf receptora | |
| RU2017102514A (ru) | Гуманизированные анти-тау-антитела | |
| JP2011520898A5 (hr) | ||
| PE20120497A1 (es) | Anticuerpo antagonista especifico para el heterodimero de alfa-4-beta-7 | |
| JP2020502046A5 (hr) | ||
| PE20120835A1 (es) | Anticuerpos anti-tnf-alfa y sus usos | |
| RU2014103498A (ru) | Применение агонистических антител против cd83 для лечения аутоиммунных заболеваний | |
| EA201000274A1 (ru) | Антитела к cd37 | |
| JP2015506912A5 (hr) |